PHARMACY FACTS

Program Updates from Louisiana Medicaid

September 6, 2024

Influenza Vaccines

Beginning September 15, 2024, the Louisiana Medicaid Pharmacy Program will reimburse enrolled pharmacies for influenza vaccines and administration of the vaccines for Medicaid recipients who are 19 years of age and older when the administering pharmacist is an enrolled Medicaid provider.

A pharmacist may administer the influenza vaccine to recipients 3 years of age and older through December 31, 2024 according to the PREP Act. Effective January 1, 2025, the reinstatement of the Louisiana Board of Pharmacy state law will allow pharmacist administration of the influenza vaccine to individuals 7 years of age and older. Counseling for vaccines will be reimbursed for recipients less than 21 years old when the vaccine is administered and criteria has been met.

The cost of the vaccine will **not** be reimbursed for recipients under the age of 19 as these vaccines are available through the Louisiana Vaccines for Children (VFC) program. Medicaid will only reimburse the administration fee for a recipient 18 years or younger.

The following chart lists influenza vaccines for influenza season 2024-2025.

| NDC | TRADE NAME | DOSAGE | STRENGTH |
|---------------|----------------------------------|---------------------|----------------|
| 19515-0810-52 | FLULAVAL TRIVALENT 2024-25 | SYRINGE | 45 mcg/.5 ml |
| 33332-0024-03 | AFLURIA TRIV 2024-25 | SYRINGE | 45 mcg/.5 ml |
| 33332-0124-10 | AFLURIA TRIVALENT 2024-25 | VIAL | 45 mcg/.5 ml |
| 49281-0724-10 | FLUBLOK TRIVALENT 2024-25 | SYRINGE | 135 mcg/0.5 ml |
| 49281-0724-88 | FLUBLOK TRIVALENT 2024-25 | SYRINGE | 135 mcg/0.5 ml |
| 58160-0884-52 | FLUARIX TRIVALENT 2024-25 | SYRINGE | 45 mcg/.5 ml |
| 70461-0024-03 | FLUAD TRIVALENT 2024-25 | SYRINGE | 45 mcg/.5 ml |
| 70461-0554-10 | FLUCELVAX TRIVALENT | VIAL | 45 mcg/.5 ml |
| 70461-0654-03 | FLUCELVAX TRIVALENT | SYRINGE | 45 mcg/.5 ml |
| 49281-0124-65 | Fluzone High-Dose Triv 2024-2025 | SYRINGE | 180 mcg/0.5 ml |
| 49281-0124-88 | Fluzone High-Dose Triv 2024-2025 | SYRINGE | 180 mcg/0.5 ml |
| 49281-0424-50 | Fluzone Triv 2024-2025 | SYRINGE | 45 mcg/.5 ml |
| 49281-0424-88 | Fluzone Triv 2024-2025 | SYRINGE | 45 mcg/.5 ml |
| 49281-0641-15 | Fluzone Triv 2024-2025 | SYRINGE | 45 mcg/.5 ml |
| 49281-0641-78 | Fluzone Triv 2024-2025 | SYRINGE | 45 mcg/.5 ml |
| 66019-0311-10 | FLUMIST TRIVALENT 2024-25 | NASAL SPRAY SYRINGE | 10E6.5 - 7.5 |

PHARMACY FACTS

Program Updates from Louisiana Medicaid

At-Home OTC COVID-19 Diagnostic Tests

Due to the end of the Public Health Emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service Act, the Pharmacy Program will end payment for at-home over the counter (OTC) COVID-19 diagnostic tests on September 30, 2024. Pharmacy claims submitted for at-home OTC COVID-19 diagnostic tests will deny starting October 1, 2024. Eligible covered beneficiaries can access their healthcare provider for vaccines, treatments and diagnostic testing as usual.

COVID Treatment: Nirmatrelvir/Ritonavir (Paxlovid™)

Effective October 1, 2024, the Louisiana Medicaid Pharmacy Program will access copayments for the COVID treatment nirmatrelvir/ritonavir (PaxlovidTM). This reinstatement of copayment does not apply to recipients who are copayment exempt.